デフォルト表紙
市場調査レポート
商品コード
1446526

組換えタンパク質治療薬CDMO市場規模、シェア、動向分析レポート:タイプ別、供給源別、適応症別、地域別、セグメント予測、2024年~2030年

Recombinant Protein Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents, Others), By Source, By Indication, By Region, And Segment Forecasts, 2024 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 173 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
組換えタンパク質治療薬CDMO市場規模、シェア、動向分析レポート:タイプ別、供給源別、適応症別、地域別、セグメント予測、2024年~2030年
出版日: 2024年02月20日
発行: Grand View Research
ページ情報: 英文 173 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

組換えタンパク質治療薬CDMO市場の成長と動向:

Grand View Research, Inc.の最新レポートによると、世界の組換えタンパク質治療薬CDMO市場は2030年までに520億米ドルに達し、2024年から2030年までのCAGRは13.95%で拡大すると予測されています。

新規組換えタンパク質治療薬の開発に関する技術革新の高まりと生物製剤の研究開発の増加は、組換えタンパク質治療薬CDMO産業にプラスの影響を与えると予測されています。新規組換えタンパク質治療薬の開発は、様々な技術革新により著しい進歩を遂げています。

組換えタンパク質は、所望のタンパク質をコードする遺伝子を宿主細胞(典型的には微生物または哺乳類細胞)に導入して目的のタンパク質を発現・生産することにより製造される生物工学的タンパク質です。現在、いくつかのタンパク質工学プラットフォーム技術が、新規タンパク質治療薬の精度と機能性をターゲットに、循環半減期を向上させるために採用されています。これらの技術はまた、生産量を高め、製品の純度を確保することも目的としています。

また、バイオ医薬品業界は、組換えタンパク質を含む生物製剤の研究開発に投資する企業が増加しており、著しい成長を遂げています。この成長は、シングルユース・バイオリアクターやその他の革新的な製造方法の採用など、製造技術の進歩によって促進されています。例えば、2024年1月、Eurofins CDMO Alphora, Inc.はパイロットスケールの生物製剤開発施設の完成を発表しました。この施設は3,300平方フィートの広大な面積を持ち、モノクローナル抗体(mAbs)や哺乳類由来のその他の治療用タンパク質の開発とスケールアップに特化しています。

さらに、がん、自己免疫疾患、代謝性疾患などの慢性疾患や複雑な疾患の世界の増加により、革新的で効果的な治療オプションに対する需要が高まっています。組み換えタンパク質治療薬は、これらの複雑な病状に対処するための多様な候補を提供します。例えば、米国がん学会の推定によると、2023年には米国で約195万8310人の新規がん患者が発生し、60万9820人ががん関連で死亡すると予測されています。さらに、オックスフォード大学が発表した研究論文によると、2022年6月に承認・上市された抗体治療薬の数は162に達し、そのうち約半数(42.6%)ががん治療用に開発されたものでした。

2023年3月、米国FDAはインサイト・コーポレーションのretifanlimab-dlwrを転移性または再発性の局所進行メルケル細胞がん(MCC)成人患者の治療薬として早期承認しました。また、がんにおける生物学的療法は、免疫反応の修復、刺激、増強をサポートします。そのため、多くの製薬・バイオ医薬品企業が、がん関連の新規治療法への投資に意欲的です。このような進歩は総体として、高品質の製品をより多く生産することを目指しています。

組換えタンパク質治療薬CDMO市場レポート・ハイライト

  • 2023年はその他セグメントが市場を独占。このセグメントの成長を牽引しているのは、血漿由来製品よりも安全な選択肢として組換えタンパク質療法が増加していることであり、これは感染症の血液感染を減らす可能性があるためです。
  • 供給源に基づくと、哺乳動物システムが2023年に67.4%の最大市場シェアを占めました。これは組換えタンパク質の供給源として哺乳動物システムの採用が増加したことに起因します。哺乳類細胞培養システムは、適切な翻訳後修飾を施した複雑なタンパク質を生産するのに有利であり、幅広い治療用途に適しています。
  • 適応症に基づくと、2023年には代謝疾患分野が21.8%の市場シェアを占めています。同分野は、高齢化社会の進展と製薬業界の旺盛な需要によって牽引されており、これが同分野の隆盛に寄与しています。
  • 北米は2023年に38.5%のシェアで市場を独占しました。同地域には強力な研究開発インフラと堅調なバイオ医薬品産業があり、これが市場成長に寄与しています。さらに米国は、組換え蛋白質治療薬を含むバイオ医薬品の製造インフラが高度に発達しています。

目次

第1章 調査手法と範囲

第2章 第2章のエグゼクティブサマリー

  • 市場スナップショット
  • セグメントのスナップショット
  • 競合情勢のスナップショット

第3章 組換えタンパク質治療薬CDMO市場:変数、動向、範囲

  • 市場系統の見通し
  • 組換えタンパク質治療薬CDMO市場力学
  • 組換えタンパク質治療薬CDMO市場:分析ツール
  • COVID-19が組換えタンパク質治療薬CDMO市場に与える影響
  • COVID-19によるバイオプロセスとアウトソーシングへの影響

第4章 組換えタンパク質治療薬CDMO市場:タイプ推定・動向分析

  • 定義と範囲
  • セグメントダッシュボード
  • 世界の組換えタンパク質治療薬CDMO市場変動分析
  • 世界の組換えタンパク質治療薬CDMO市場規模と動向分析、タイプ別、2018年から2030年

第5章 組換えタンパク質治療薬CDMO市場:ソース推定・動向分析

  • 定義と範囲
  • セグメントダッシュボード
  • 世界の組換えタンパク質治療薬CDMO市場変動分析
  • 世界の組換えタンパク質治療薬CDMO市場規模と動向分析、ソース別、2018年から2030年

第6章 組換えタンパク質治療薬CDMO市場:適応症の推定・動向分析

  • 定義と範囲
  • セグメントダッシュボード
  • 世界の組換えタンパク質治療薬CDMO市場変動分析
  • 世界の組換えタンパク質治療薬CDMO市場規模と動向分析、適応症別、2018~2030年

第7章 組換えタンパク質治療薬CDMO市場:タイプ、ソース、適応症別の地域推定・動向分析

  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 市場規模と予測トレンド分析、2018年から2030年:
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 企業の分類
  • 組換えタンパク質治療薬CDMO市場シェア分析、2023年
  • Major Deals and Strategic Alliances Analysis
    • 戦略マッピング
    • 拡大
    • パートナーシップ
    • 買収
  • ベンダー情勢
    • Key company market share analysis, 2023
    • Richter-Helm BioLogics
    • Lonza
    • Catalent, Inc
    • FUJIFILM Diosynth Biotechnologies
    • WuXi Biologics
    • Curia Global, Inc.
    • Batavia Biosciences BV
    • HALIX BV
    • BIOVIAN
    • Enzene Biosciences Ltd
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 5 North America Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 6 U.S. Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 8 U.S. Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 9 Canada Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 11 Canada Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Europe Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 14 Europe Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 15 Europe Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 16 UK Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 17 UK Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 18 UK Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 19 Germany Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 20 Germany Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 21 Germany Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 22 France Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 23 France Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 24 France Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Italy Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 26 Italy Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 27 Italy Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Spain Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 29 Spain Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 30 Spain Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 31 Denmark Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 32 Denmark Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 33 Denmark Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 34 Sweden Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 35 Sweden Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 36 Sweden Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 37 Norway Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 38 Norway Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 39 Norway Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Japan Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 45 Japan Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 46 Japan Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 47 China Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 48 China Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 49 China Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 50 India Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 51 India Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 52 India Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 53 Australia Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 54 Australia Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 55 Australia Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 56 Thailand Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 57 Thailand Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 58 Thailand Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 59 South Korea Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 61 South Korea Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Latin America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 64 Latin America Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 65 Brazil Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 66 Brazil Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 67 Brazil Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 68 Mexico Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 69 Mexico Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 70 Mexico Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 71 Argentina Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 72 Argentina Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 73 Argentina Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 74 MEA Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 76 MEA Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 77 MEA Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 78 South Africa Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 79 South Africa Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 80 South Africa Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 84 UAE Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 85 UAE Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 86 UAE Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)
  • Table 87 Kuwait Recombinant Protein Therapeutics CDMO market, by type, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Recombinant Protein Therapeutics CDMO market, by source, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Recombinant Protein Therapeutics CDMO market, by indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Recombinant protein therapeutics CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market outlook, 2022 (USD Billion)
  • Fig. 16 Ancillary market outlook, 2022 (USD Billion)
  • Fig. 17 Recombinant protein therapeutics CDMO market dynamics
  • Fig. 18 Porter's five forces analysis
  • Fig. 19 PESTEL analysis
  • Fig. 20 Recombinant protein therapeutics CDMO market type outlook: Segment dashboard
  • Fig. 21 Recombinant protein therapeutics CDMO market, by type segment: Market share, 2023 & 2030
  • Fig. 22 Growth hormones market, 2018 - 2030 (USD Million)
  • Fig. 23 Interferons market, 2018 - 2030 (USD Million)
  • Fig. 24 Vaccines market, 2018 - 2030 (USD Million)
  • Fig. 25 Immunostimulating agents market, 2018 - 2030 (USD Million)
  • Fig. 26 Others market, 2018 - 2030 (USD Million)
  • Fig. 27 Recombinant protein therapeutics CDMO market source outlook: Segment dashboard
  • Fig. 28 Recombinant protein therapeutics CDMO market, by source segment: Market share, 2023 & 2030
  • Fig. 29 Mammalian systems market, 2018 - 2030 (USD Million)
  • Fig. 30 Microbial systems market, 2018 - 2030 (USD Million)
  • Fig. 31 Others market, 2018 - 2030 (USD Million)
  • Fig. 32 Recombinant protein therapeutics CDMO market indication outlook: Segment dashboard
  • Fig. 33 Recombinant protein therapeutics CDMO market, by indication segment: Market share, 2023 & 2030
  • Fig. 34 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 35 Infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 36 Immunological disorders market, 2018 - 2030 (USD Million)
  • Fig. 37 Metabolic disorders market, 2018 - 2030 (USD Million)
  • Fig. 38 Haematological disorders market, 2018 - 2030 (USD Million)
  • Fig. 39 Others market, 2018 - 2030 (USD Million)
  • Fig. 40 Regional market: Key takeaways
  • Fig. 41 Regional marketplace: Key takeaways
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 North America recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 U.S. recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Canada recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 48 Europe recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 UK recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Germany recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 France recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Italy recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Spain recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Denmark recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Norway recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Japan recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 China recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 India recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Australia recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Clinical trial approval process in South Korea
  • Fig. 76 South Korea recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Thailand recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 79 Latin America recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Brazil recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Mexico recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Argentina recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 86 MEA recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 South Africa recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Saudi Arabia recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Clinical trial authorization process UAE
  • Fig. 93 UAE recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Kuwait recombinant protein therapeutics CDMO market, 2018 - 2030 (USD Million)
  • Fig. 96 Market participant categorization
  • Fig. 97 Market participant categorization
  • Fig. 98 Heat map analysis
目次
Product Code: GVR-4-68040-116-2

Recombinant Protein Therapeutics CDMO Market Growth & Trends:

The global recombinant protein therapeutics CDMO market is expected to reach USD 52.0 billion by 2030 and is expected to expand at a CAGR of 13.95% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing technological innovations about the development of novel recombinant protein therapeutics and rising research and development for biologics are anticipated to influence the recombinant protein therapeutics CDMO industry positively. The development of novel recombinant protein therapeutics has observed significant advancements due to various technological innovations.

Recombinant proteins are bioengineered proteins produced by introducing the gene encoding the desired protein into a host cell, typically a microorganism or a mammalian cell, to express and produce the protein of interest. Several protein engineering platform technologies are currently employed to enhance the circulating half-life, targeting the precision and functionality of novel therapeutic protein drugs. These technologies also aim to boost production yield and ensure product purity.

Besides, the biopharmaceutical industry has witnessed significant growth, with an increasing number of companies investing in research and development of biologics, including recombinant proteins. This growth has been facilitated by advancements in manufacturing technologies, including adopting single-use bioreactors and other innovative production methods. For instance, in January 2024, Eurofins CDMO Alphora, Inc. announced the successful completion of its pilot-scale biologics development facility. With an expansive area of 3,300 square feet, this facility is exclusively dedicated to developing and scaling monoclonal antibodies (mAbs) and other therapeutic proteins derived from mammalian sources.

Moreover, the global increase in the prevalence of chronic and complex diseases, such as cancer, autoimmune disorders, & metabolic diseases, has increased the demand for innovative and effective therapeutic options. Recombinant protein therapeutics offer a diverse range of candidates to address these complex medical conditions. For instance, based on estimates from the American Cancer Society, it is projected that in 2023, there will be approximately 1,958,310 new cases of cancer and 609,820 cancer-related deaths in the U.S. Furthermore, according to a research article published by Oxford University, in June 2022, the number of approved and marketed antibody therapies reached 162, nearly half of which (42.6%) were being developed for the treatment of cancer.

In March 2023, the U.S. FDA granted accelerated clearance to Incyte Corporation's retifanlimab-dlwr for the treatment of adult patients with metastatic or recurrent, locally advanced Merkel Cell Carcinoma (MCC). Besides, biological therapy in cancer supports repairing, stimulating, or enhancing the immune response. Therefore, many pharmaceutical & biopharmaceutical companies are willing to invest in cancer-related novel treatments.Such advancements collectively aim to achieve a higher yield of quality products.

Recombinant Protein Therapeutics CDMO Market Report Highlights:

  • The others segment dominated the market in 2023. The segment growth is driven by increasing recombinant protein therapies as a safer option than plasma-derived products owing to the potential to reduce bloodborne transmission of infectious diseases
  • Based on the source, mammalian systems held the largest market share of 67.4% in 2023 attributed to an increase in the adoption of mammalian systems for sourcing recombinant proteins. Mammalian cell culture systems offer advantages in producing complex proteins with appropriate post-translational modifications, making them suitable for a wide range of therapeutic applications
  • Based on indication, the metabolic disorders segment held a market share of 21.8% in 2023. The segment is driven by a growing aging population, and robust demand for pharmaceutical industry, which has contributed to its prominence in this field
  • North America dominated the market with a share of 38.5% in 2023. The region has a strong R&D infrastructure and a robust biopharmaceutical industry, which has contributed to the market growth. Furthermore, the U.S. has a sophisticated and well-developed manufacturing infrastructure for biopharmaceuticals, including recombinant protein therapeutics

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's InternalL Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
    • 1.3.5. Details Of Primary Research
  • 1.4. Information Or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. Market Definitions
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective - 1
    • 1.10.2. Objective - 2
    • 1.10.3. Objective - 3
    • 1.10.4. Objective - 4

Chapter 2. Chapter 2 Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Recombinant Protein Therapeutics CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Recombinant Protein Therapeutics CDMO Market Dynamics
    • 3.2.1. Market Driver Impact Analysis
      • 3.2.1.1. Rising Adoption Of Biologics And Biosimilars
      • 3.2.1.2. Technological Innovations About The Development Of Novel Recombinant Protein Therapeutics
      • 3.2.1.3. Increasing Rate Of Clinical Research To Boost Demand For Recombinant Protein Therapeutics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory Hurdles
      • 3.2.2.2. Challenges Related To Quality Control
  • 3.3. Recombinant Protein Therapeutics CDMO Market: Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
  • 3.4. Impact Of Covid-19 On Recombinant Protein Therapeutics CDMO Market
  • 3.5. Covid-19 Impact On Bioprocessing And Outsourcing
    • 3.5.1. Clinical Trial Supply & Logistics Services: Impact Of Covid-19
    • 3.5.2. Supply Chain
    • 3.5.3. Activities By CDMOs Increased Post-Covid-19 Pandemic, Supporting The Development Of Recombinant Protein Therapeutics
    • 3.5.4. Changes In The Long Term

Chapter 4. Recombinant Protein Therapeutics CDMO Market: Type Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Growth Hormones
    • 4.1.2. Interferons
    • 4.1.3. Vaccines
    • 4.1.4. Immunostimulating Agents
    • 4.1.5. Others
  • 4.2. Segment Dashboard
  • 4.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
  • 4.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
    • 4.4.1. Growth Hormones
      • 4.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.2. Interferons
      • 4.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.3. Vaccines
      • 4.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.4. Immunostimulating Agents
      • 4.4.4.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 5. Recombinant Protein Therapeutics CDMO Market: Source Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Mammalian Systems
    • 5.1.2. Microbial Systems
    • 5.1.3. Others
  • 5.2. Segment Dashboard
  • 5.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
  • 5.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Source, 2018 to 2030 (USD Million)
    • 5.4.1. Mammalian Systems
      • 5.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 5.4.2. Microbial Systems
      • 5.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 5.4.3. Others
      • 5.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 6. Recombinant Protein Therapeutics CDMO Market: Indication Estimates & Trend Analysis

  • 6.1. Definitions and Scope
    • 6.1.1. Oncology
    • 6.1.2. Infectious Diseases
    • 6.1.3. Immunological Disorders
    • 6.1.4. Metabolic Disorders
    • 6.1.5. Haematological Disorders
    • 6.1.6. Others
  • 6.2. Segment Dashboard
  • 6.3. Global Recombinant Protein Therapeutics CDMO Market Movement Analysis
  • 6.4. Global Recombinant Protein Therapeutics CDMO Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
    • 6.4.1. Oncology
      • 6.4.1.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.2. Infectious Diseases
      • 6.4.2.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.3. Immunological Disorders
      • 6.4.3.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.4. Metabolic Disorders
      • 6.4.4.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.5. Haematological Disorders
      • 6.4.5.1. Market Estimates and Forecast 2018 to 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market Estimates and Forecast 2018 to 2030 (USD Million)

Chapter 7. Recombinant Protein Therapeutics CDMO Market: Regional Estimates & Trend Analysis by Type, Source, Indication

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Scenario
      • 7.4.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Scenario
      • 7.4.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Scenario
      • 7.5.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Scenario
      • 7.5.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Scenario
      • 7.5.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Scenario
      • 7.5.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Scenario
      • 7.5.6.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Scenario
      • 7.5.7.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Scenario
      • 7.5.8.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Scenario
      • 7.5.9.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Scenario
      • 7.6.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Scenario
      • 7.6.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Scenario
      • 7.6.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Scenario
      • 7.6.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Scenario
      • 7.6.6.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.6.7. South Korea
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Scenario
      • 7.6.7.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Scenario
      • 7.7.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.7.3. Mexico
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Scenario
      • 7.7.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.7.4. Argentina
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Scenario
      • 7.7.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Scenario
      • 7.8.2.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Scenario
      • 7.8.3.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Scenario
      • 7.8.4.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Scenario
      • 7.8.5.4. Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Recombinant Protein Therapeutics CDMO Market Share Analysis, 2023
  • 8.3. Major Deals and Strategic Alliances Analysis
    • 8.3.1. Strategy Mapping
    • 8.3.2. Expansion
    • 8.3.3. Partnerships
    • 8.3.4. Acquisitions
  • 8.4. Vendor Landscape
    • 8.4.1. Key company market share analysis, 2023
    • 8.4.2. Richter-Helm BioLogics
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Lonza
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Catalent, Inc
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. FUJIFILM Diosynth Biotechnologies
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. WuXi Biologics
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Curia Global, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Batavia Biosciences B.V.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. HALIX B.V.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. BIOVIAN
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Enzene Biosciences Ltd
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives